[Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis].
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000451:nursing*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000451:nursing*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D008134:Long-Term Care; D008727:Methotrexate / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D008727:Methotrexate